No abstract

The article is devoted to third-generation slow-modifying chondroprotective drug therapy including Alflutop. The evidence-based  medicine showed and substantiated in vitro effect of the drug on the pathogenetic processes in the cartilage tissue, its promotion  of the inflammation regression in the musculoskeletal system. The authors present a series of clinical studies of top osteoarthritis doctors, which showed that Alflutop had an anti-inflammatory, chondroprotective, analgesic effect, and that the administration of  the drug allowed patients to reduce the doses of NSAIDs, and it could be used in patients with comorbid diseases.

No abstract